Review of clinical guidelines for the treatment of children with confirmed coronavirus infection COVID-19: a clinical pharmacologist’s view


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A pandemic caused by the coronavirus SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), which until February 11, 2020 had the temporary name 2019-nCoV (COVID-19), with a developing clinic for severe acute respiratory syndrome, represents an unprecedented opportunity to identify effective drugs to prevent and treat this infection. Given the rapid pace of scientific discovery and clinical evidence, clinicians need the right information on effective medical treatments for this infection, especially in children.

Full Text

Restricted Access

About the authors

Svetlana B. Erofeeva

Krasnogorsk City Hospital № 1; Pirogov Medical University

Email: erofsb@mail.ru
Cand. Sci. (Med.), Clinical Pharmacologist; Associate Professor, Department of Clinical Pharmacology Krasnogorsk, Russia; Moscow, Russia

E. P Smirnova

M.E. Zhadkevich City Clinical Hospital; Pirogov Medical University

Moscow, Russia; Moscow, Russia

References

  1. Guan W.J., Ni Z.Y., Hu Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl Med. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032.
  2. Stokes E.K., Zambrano L.D., Anderson K.N., et al. Coronavirus Disease 2019 Case Surveillance -United States, January 22-May 30, 2020. MMWR -Morb Mortal Wkly Rep. 2020;69(24):759-65. doi: 10.15585/mmwr.mm6924e2.
  3. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. doi: 10.1001/jama.2020.2648.
  4. CDC. Demographic Trends of COVID-19. URL: https://www.cdc.gov/covid-data-tracker/index.html#demographics. Data retrieved: July 27, 2020.
  5. Методические рекомендации «Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей». Версия 2 (утверждена Минздравом России) 03.07.2020. [Methodical recommendations «Features of the clinical manifestations and treatment of the disease caused by a new coronavirus infection (COVID-19) in children.» Version 2 (approved by the Ministry of Health of Russia) 07/03/2020. (In Russ.)].
  6. Kim L., Whitaker M., O'Halloran A., et al. Hospitalization Rates and Characteristics of Children Aged №18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. MMWR - Morb Mortai Wkly Rep. 2020;69(32):1081-1088. doi: 10.15585/mmwr.mm6932e3.
  7. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morbidity and Mortality Weekly Report. 2020;69(14):422-26. doi: 10.15585/mmwr.mm6914e4.
  8. Klompas M., Branson R., Eichenwald E.C., et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(8):915-36. Doi: https://doi.org/10.1086/677144.
  9. Paules C.I., Marston H.D., Fauci A.S. Coronavirus infections-more than just the common cold. JAMA. 2020;323(8):707-8. Doi: https://doi.org/10.1001/jama.2020.0757.
  10. Романов Б.К. Коронавируснаяинфекция COVID-2019. Безопасность и риск фармакотерапии. 2020;8(1):3-8. Doi: https://doi.org/10.30895/2312-7821-2020-8-1-3-8.
  11. Dong Y., Mo X., Hu Y., et al. Epidemiological characteristics of 2,143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. Pediatrics. 2020;145(6):e20200702.
  12. Centers for Disease Control and Prevention. Coronavirus Disease 2019 in Children-United States, February 12-April 2,2020. Available at: URL: https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e4
  13. Cui X., Zhang T., Zheng J., et al. Children with coronavirus disease 2019 (covid-19): a review of demographic, clinical, laboratory and imaging features in 2,597 pediatric patients. J Med Virol. 2020;10.1002/mv.26023. doi: 10.1002/jmv.26023.
  14. Livingston E., Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020 Mar 17. doi: 10.1001/jama.2020.4344.
  15. Tagarro A, Epalza C., Santos M., et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020 Apr 8;e201346. doi: 10.1001/jamapediatrics.2020.1346.
  16. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines National Institutes of Health. URL: https://www.covid19treatmentguidelines.nih.gov/special-populations/children/
  17. Royal College of Paediatrics and Child Health. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020. URL: https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf. Accessed: May 28, 2020.
  18. Riphagen S., Gomez X., Gonzalez-Martinez C., et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395( 1023 7): 1607-608. doi: 10.1016/S0140-6736(20)31094-1.
  19. Verdoni L., Mazza A., Gervasoni A., et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771-78. doi: 10.1016/S0140-6736(20)31103-X.
  20. Toubiana J., Poirault C., Corsia A., et al. Outbreak of Kawasaki disease in children during COVID-19 pandemic: a prospective observational study in Paris, France. medRxiv. 2020. Doi: https://doi.org/10.1101/2020.05.10.20097394
  21. Chiotos K., Hayes M., Kimberlin D.W., et al. Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc. 2020 Apr 22;piaa045. doi: 10.1093/jpids/piaa045.
  22. Gilead Sciences. Remdesivir (GS-5734) investigator's brochure. Edition 5. February 21, 2020.
  23. Food and Drug Administration. Remdesivir by Gilead Sciences: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of treatment. 2020. URL: https://www.fda.gov/safety/medical-product-safety-information/remdesivir-gilead-sciences-fda-warns-newly-discovered-potential-drug-interaction-may-reduce. Accessed: July 2, 2020.
  24. Mulangu S., Dodd L.E., Davey R.T., Jr., et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019:381(24):2293-303. doi: 10.1056/NEJMoa1910993.
  25. Dornemann J., Burzio C., Ronsse A., et al. First newborn baby to receive experimental therapies survives ebola virus disease. J Infect Dis. 2017;215(2):171-74. doi: 10.1093/infdis/iw493.
  26. Liu J., Cao R., Xu M., et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:1-4. doi: 10.1038/s41421-019-0132-8.
  27. Gautret P., Lagier J.-C., Parola P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949.
  28. Sankar J., Dhochak N., Kabra S.K., Lodha R. COVID-19 in Children: Clinical Approach and Management. Indian J Pediatr. 2020 Apr 27:1-10. doi: 10.1007/s12098-020-03292-1.
  29. Morse J.S., Lalonde T., Xu S., Liu W.R. learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21:730-38. doi: 10.1002/cbic.202000047.
  30. Russell B., Moss C., George G., et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19 - a systematic review of current evidence. Ecancer. 2020. doi: 10.3332/ecancer.2020.1022.
  31. Singhal T A review of coronavirus disease-2019 (COVID-19) Indian J Pediatr. 2020;87:281-86. doi: 10.1007/s12098-020-03263-6.
  32. Национальные рекомендации по диагностике и лечению пневмонии, вызванной 2019-nCoV (4-е изд.). Национальная комиссия здравоохранения и Национальное административное управление традиционной китайской медицины. URL: https://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67/files/7a93 09111267475a99d4306962c8bf78.pdf
  33. Chu C.M. Role of Lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252-56. doi: 10.1136/thorax.2003.012658.
  34. Arabi Y.M., Alothman A., Balkhy H.H., et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-ß1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:81. doi: 10.1186/s13063-017-2427-0.
  35. Lu Q., Wang X.F, Qiang Y., et al. Expert consensus on the diagnosis and treatment of viral pneumonia in children. Zhongguo Shi Yong Er Ke Za Zhi. 2019;34:801-7.
  36. Arabi Y.M., Mandourah Y., Al-Hameed F., et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757-67. doi: 10.1164/rccm.201706-1172OC.
  37. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Jan 11, 2020. URL: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_2. Accessed: 30 Jan 30 2020.
  38. Wang X.F., Deng L., Liu J.R., et al. Guidelines for the diagnosis and treatment of adenovirus pneumonia in children (2019 edition). Chin J Cli Infect Dis. 2019;12:161-66.
  39. Group R.C., Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med. 2020 Jul 17;NEJMoa2021436. doi: 10.1056/NEJMoa2021436.
  40. Gardner R.A., Ceppi F., Rivers J., et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134(24):2149-58. doi: 10.1182/blood.2019001463.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies